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The incidence of multiple drug resistant tuberculosis
(MDR-TB) is increasing worldwide, limiting the effec-
tiveness of conventional drug therapies. Fluoroquinolone
antibiotics may offer an effective drug treatment option
for susceptible and MDR-TB.
OBJECTIVE: To review clinical and non-clinical evi-
dence of the efficacy, safety, and product characteristics
of fluoroquinolones with regard to their potential use in
the treatment of pulmonary TB.
METHODS: This review focused on fluoroquinolones
that have been approved for marketing in the US. Char-
acteristics assessed included: dosage; dosing frequency; ap-
proved indications; treatment duration; pharmacodynamics/
pharmacokinetics; adverse events; drug interactions; mu-
tagenic and teratogenic potential; structure-function relation-
ships; long-term use; Cmax and AUC ratios for M. tuberculo-
sis; and efficacy against susceptible and MDR-TB as reported
from in vitro, animal model, and clinical assessments. Infor-
mation was taken from the Physician’s Desk Reference, Drug
Facts and Figures, product monographs, medical literature in-
cluding clinical trial reports, the Food and Drug Adminis-
tration’s Center for Drug Evaluation and Research (CDER)
approval packages for fluoroquinolones, and expert opinion.
RESULTS: The earliest introduced fluoroquinolones,
such as norfloxacin and enoxacin, are least likely to be
useful in treating TB, due to low clinical efficacy. Trova-
floxacin is also ineffective against TB, and has undesir-
able adverse effects. Some fluoroquinolones, such as
sparfloxacin, offer efficacy against TB, but also have
problematic adverse effects. Ciprofloxacin and ofloxacin
are moderately effective against TB, and have generally
favorable characteristics. Levofloxacin has shown effi-
cacy in vitro and in animal models, as well as favorable
drug interaction and adverse event profiles, but human
efficacy is inconclusive. Moxifloxacin and gatifloxacin
may offer similar profiles to levofloxacin, but clinical
trial efficacy data is insufficient to draw conclusions.
CONCLUSIONS: While no one fluoroquinolone pos-
sesses all of the desirable characteristics for a new pulmo-
nary TB therapy, there are a number of candidates that
may have clinical efficacy and generally favorable profiles.
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ESTIMATING THE RETURN ON INVESTMENT 
FOR TUBERCULOSIS DRUGS
Mauskopf JA, Bell L, Neighbors D, Dombeck M
RTI Health Solutions, Research Triangle Park, NC, USA
In 1997, there were approximately eight million new ac-
tive cases of tuberculosis but only two percent of cases
were in established market economies. There is a need for
new drugs that could shorten treatment times but a con-
cern about return on investment (ROI) in this disease
area.
OBJECTIVE: To measure the ROI for a tuberculosis
drug development program.
METHODS: ROI may be measured by computing the net
present value of the estimated costs and revenue streams.
An EXCEL spreadsheet model was prepared that had a
25-year time horizon, starting as the molecule entered
Phase 1 trials. The model included costs for clinical trials,
non-clinical development, manufacturing development,
cost of goods, and sales and marketing. Revenues were
estimated for each year after launch assuming three years
to peak sales, five years at peak sales, and a 20 year
patent life from the start of Phase 1. A discount rate of 12
percent was used to compute the net present value. Alter-
native cost scenario models were based on whether time
from start of Phase 1 to launch was 10 years (normal) or
seven years (rapid) and whether clinical trials were con-
ducted in the US or Uganda. Alternative revenue scenar-
ios were also modeled.
RESULTS: Total discounted costs were $13.9 million,
$21.3 million, $9.0 million, and $13.7 million for the
normal US, rapid US, normal Uganda, and rapid Uganda
scenarios and medium revenue stream. Total discounted
revenue for the medium revenue assumption was $28.0
million at normal development and $46.6 million at
rapid development. Net present values ranged between
$6.8 million and $162.1 million for the 12 combinations
of costs and revenues modeled.
CONCLUSIONS: Drugs for tuberculosis will have a pos-
itive return on investment if molecules can be identified
when they enter Phase 1 of development.
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Bedouch P, Labarère J, Mareau E, Allenet B, Calop J, François P
Grenoble University Hospital, Grenoble, France
OBJECTIVES: To assess the compliance with antibiotic
prophylaxis practices and identify the factors associated
with practice variations in total hip replacement (THR)
surgery.
METHODS: We carried out a retrospective survey of
medical records in the orthopedic surgery department in
a 2,200-bed university hospital. A sample of 416 patients
undergoing THR from January 1999 to December 2000
was drawn. Practice conformity was evaluated based on
French guidelines for good clinical practice concerning
antibiotic prophylaxis in orthopedic surgery. Five major
criteria were used: antibiotic prophylaxis use; choice of
molecule; dosage at first injection; time between first in-
jection and incision; total duration. A multilevel hierar-
chical logistic regression analysis was performed using
global conformity as the dependant variable.
RESULTS: Among the 386 medical records analyzed, an-
tibiotic prophylaxis was used in 366 (95%) interventions.
The choice of molecule was consistent with the reference
for 258 (70%) patients. Among patients receiving a rec-
ommended molecule, dosage and timing of first injection
were consistent respectively for 98% (290/296) and 80%
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(236/296). The total duration of treatment was restricted
to 48 hours for 360 of 366 (98%) patients. Global con-
formity, defined as the combination of the five major cri-
teria, accounted for 52% (201/386) of patients undergo-
ing THR surgery. After multivariate analysis, a statistically
significant association was found between the global con-
formity and the prescribers (p  0.03). The interventions
during 1999 (AOR 0.61; 95% CI 0.40–0.92) were associ-
ated with a risk of non-conformity. Adherence to guide-
lines for antibiotic prophylaxis practice was not associated
with prescriber’s characteristics.
CONCLUSIONS: Although French guidelines were re-
cently published, the appropriateness of antibiotic pro-
phylaxis in THR surgery could still be enhanced espe-
cially in terms of the rational choice of a molecule and
timing of the first injection.
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PROPHYLAXIS AGAINST RSV, VARICELLA 
AND PNEUMOCOCCAL INFECTIONS:
ECONOMIC-BASED DECISION-MAKING
Strutton DR, Stang PE
Galt Associates, Sterling, VA, USA
OBJECTIVE: To facilitate evaluation and comparison of
cost-effectiveness results for varicella and pneumococcal
conjugate vaccination with respiratory syncytial virus
(RSV) prophylaxis using palivizumab by standardizing
cost and benefit results from published studies.
METHODS: MEDLINE search identified English lan-
guage cost-effectiveness studies for the three interven-
tions. Prophylaxis recommendations by the American
Academy of Pediatrics were examined. Results were dis-
counted by 5% and costs were inflated to 1997 dollars
using the Medical Care component of the CPI.
RESULTS: From the societal perspective, the cost per life
year saved was $144,000 for pneumococcal vaccine and
$54,000 for palivizumab RSV prophylaxis, but varicella
vaccine saved money. From the payers’ perspective, the
cost per life year saved was $278,000 for pneumococcal
vaccine, $55,000 for RSV prophylaxis and $23,000 for va-
ricella vaccine. Payers’ cost to avoid hospitalization for
RSV infection was $13,000. An avoided varicella case cost
$6 and it cost $2400 to avoid a major varicella sequela,
and each case of pneumococcus avoided cost $103,000.
CONCLUSION: Prevention of avoidable childhood mor-
bidity and mortality may cause incremental costs to payers
but would be a rational policy from a societal point of view.
Costs associated with RSV prophylaxis of high-risk infants
with palivizumab do not appear unreasonable compared
with the cost-effectiveness of two recent vaccines recom-
mended for universal use in healthy children in the US.
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THE FIRST STEP TO GENERATING UTILITY 
FROM QUALITY OF LIFE: A COMPARISON OF 
ITEM PREFERENCES AND ITEM SEVERITY
Doward LC1, Whalley D1, McKenna SP1, Meads DM1, Cook 
SA1, Langley PC2
1Galen Research, Manchester, UK; 23M Pharmaceuticals, St 
Paul, MN, USA
OBJECTIVE: The Recurrent Genital Herpes Quality of
Life questionnaire (RGHQoL) is a needs-based quality of
life (QoL) instrument specifically for use with recurrent
genital herpes (RGH). It has been shown to have excel-
lent psychometric properties. However, it cannot cur-
rently be used in the calculation of utility for economic
analyses. Existing utility instruments cover symptoms
and functioning, rather than QoL. Concern has been ex-
pressed over their relevance for RGH and, consequently,
their ability to show differences between interventions.
The aim of this project is to explore the potential for us-
ing the RGHQoL to produce meaningful utility scores.
The first stage was to investigate whether a preference
elicitation exercise was required or whether RGHQoL re-
sponses could be incorporated directly into utility analy-
ses. This paper presents findings from the first stage.
METHODS: Structured interviews were conducted with
100 RGH patients. Patients undertook preference exer-
cises (paired comparison and ranking) with six RGHQoL
items and completed the RGHQoL. Thurstone’s law of
comparative judgement was used to calculate item prefer-
ence weights. These were compared with item severity
weights derived via application of the Rasch model to
RGHQoL responses.
RESULTS: Item ordering of severity was: B-E-D-C-A-F
(paired comparisons), B-C-D-E-A-F (ranking) and F-A-D-
C-E-B (Rasch severity). The paired comparisons and
ranking exercises resulted in different ordering of some
items, even though the methods are considered direct al-
ternatives for eliciting preference information. The Rasch
severity and preference weights provided very different
orderings. For example, the most severe item according
to patients’ responses to the RGHQoL was judged the
least severe in the paired comparison and ranking situa-
tions.
CONCLUSIONS: The results suggest that individuals’
ratings of what would have the most impact on them are
very different from what actually has an impact. RGHQoL
responses cannot be used directly in place of preference
elicitation.
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THE DEVELOPMENT AND VALIDATION OF THE 
INFLUENZA DAILY DISRUPTION 
QUESTIONNAIRE (IDDQ)
Wild DJ1, Doll HA1, Gyldmark M2, Hakim Z3
1Oxford Outcomes, Oxford, UK; 2 F. Hoffman-La Roche Ltd, 
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OBJECTIVES: This paper reports on the development of
and psychometric validation of the Influenza Daily Dis-
ruption Questionnaire (IDDQ), a short new instrument
